New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:16 EDTCASI, BDSI, DISH, ENDP, NQ, SPPI, ARNA, GTATOn The Fly: Pre-market Movers
HIGHER: DISH (DISH), up 2.4% following positive mention in this weekend's Barron's, contending the shares could climb 20%... BioDelivery Sciences (BDSI), up 15% after announcing results from its Endo buprenorphine trial with an Endo (ENDP) division... CASI Pharmaceuticals (CASI), up 3.7% after confirming that it received FDA orphan drug designation for a drug... Spectrum (SPPI), up 3% after being granted accelerated approval for Beleodaq from FDA. LOWER: GT Advanced (GTAT), down 10% after downgraded at UBS and Cannaccord... NQ Mobile (NQ), down 3.5% after Muddy Waters says the company has likely already decided to fire PwC... Arena Pharmaceuticals (ARNA), down 3% after Chairman, President and CEO Jack Lief sold 223,525 shares of the company's common stock pursuant to a Rule 10b5-1 trading plan on July 1, according to a regulatory filing from late Thursday.
News For DISH;GTAT;NQ;BDSI;ARNA;ENDP;CASI;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:14 EDTBDSIBioDelivery Sciences files $150M mixed securities shelf
Subscribe for More Information
10:48 EDTBDSIOptions with increasing implied volatility
Subscribe for More Information
July 1, 2015
18:39 EDTBDSIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 6.6%. ALSO HIGHER: Xoom (XOOM), up 22% after announcing company to be acquired by PayPal... BioDelivery Sciences (BDSI), up 4.7% after Point72 Asset Management reports 5.5% passive stake in the company... Green Brick Partners (GRBK), up 7.5% after Third Point reports 16.9% stake in the company.
16:13 EDTBDSIPoint72 Asset Management reports 5.5% passive stake in BioDelivery Sciences
Subscribe for More Information
15:23 EDTDISHDISH's Ergen awaits AT&T-DirecTV approval before more T-Mobile talks, FBN says
Subscribe for More Information
09:41 EDTNQRosenblatt sees increased likelihood of asset sales for NQ Mobile
June 29, 2015
07:36 EDTSPPISpectrum coverage assumed with a Buy at H.C. Wainwright
Subscribe for More Information
June 25, 2015
16:42 EDTDISHFCC Chairman outlines changes to future spectrum auctions
Subscribe for More Information
June 24, 2015
07:02 EDTSPPISpectrum announces publication of Beleodaq data in Journal of Clinical Oncology
Spectrum Pharmaceuticals announced the publication of results from the pivotal BELIEF -- CLN-19 -- Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology, the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen O’Connor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies. Beleodaq, previously known as belinostat, is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The primary endpoint of the BELIEF study was ORR as assessed centrally by an Independent Review Committee using the International Working Group criteria. The ORR in the 120 evaluable patients was 25.8%, including 13 Complete Responses and 18 Partial Responses. Secondary endpoints included a median DoR of 13.6 months by IWG criteria and 8.4 months to disease progression or death, with the longest ongoing patient at ≥36 months. The most common Grade 3/4 adverse events were anemia, thrombocytopenia, dyspnea, and neutropenia. No clinically relevant ECG changes were identified, and cardiovascular monitoring of ECGs is not required at baseline or during treatment. In this pivotal study, monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major disease subtypes, irrespective of the number or type of prior therapies and with a low incidence of Grade 3/4 thrombocytopenia.
June 23, 2015
10:00 EDTCASIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at BofA/Merrill... Angie's List (ANGI) initiated with a Hold at Topeka... Avenue Financial (AVNU) initiated with an Equal Weight at Stephens... CASI Pharmaceuticals (CASI) initiated with a Buy at H.C. Wainwright... Corindus (CVRS) initiated with a Buy at Stifel... Coupons.com (COUP) initiated with a Market Perform at William Blair... Five Below (FIVE) initiated with an Outperform at RBC Capital... Franklin Financial Network (FSB) initiated with an Equal Weight at Stephens... Galmed (GLMD) initiated with a Buy at H.C. Wainwright... Genesis Healthcare (GEN) initiated with a Neutral at Susquehanna... Groupon (GRPN) initiated with a Hold at Topeka... GrubHub (GRUB) initiated with a Buy at Topeka... Hercules Technology (HTGC) initiated with a Buy at Compass Point... Immersion (IMMR) initiated with a Buy at Craig-Hallum... Lipocine (LPCN) initiated with a Buy at Canaccord... NeoGenomics (NEO) initiated with a Buy at BTIG... Novadaq (NVDQ) initiated with a Neutral at BTIG... Perrigo (PRGO) initiated with an Outperform at BMO Capital... Signal Genetics (SGNL) initiated with a Buy at Chardan... Standard Motor Products (SMP) initiated with a Neutral at CL King... United Community Financial (UCFC) initiated with a Market Perform at Keefe Bruyette... WP Glimcher (WPG) initiated with a Neutral at Goldman... WhiteWave (WWAV) initiated with a Buy at Maxim... Yelp (YELP) initiated with a Buy at Topeka.
07:18 EDTCASICASI Pharmaceuticals initiated with a Buy at H.C. Wainwright
Subscribe for More Information
June 22, 2015
15:04 EDTDISHT-Mobile could abandon DISH for Comcast, Forbes contributor says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use